MoneyWorks4Me

Alembic Pharmaceuticals reports 12% rise in Q1 consolidated net profit

04 Aug 2026 Evaluate

Alembic Pharmaceuticals has reported its results for the first quarter ended June 30, 2026 (Q1FY27).

The company has reported a 90.26% rise in its net profit at Rs 196.96 crore for the quarter ended June 30, 2026, as compared to Rs 103.52 crore for the same quarter in the previous year. Total income increased by 25.31% to Rs 1,882.10 crore for Q1FY27 as compared to Rs 1,501.96 crore for the corresponding quarter of the previous year.

On a consolidated basis, the company has reported a 12.11% rise in its net profit at Rs 173.07 crore for Q1FY27, as compared to Rs 154.38 crore for the same quarter in the previous year. Total income increased by 26.06% to Rs 2,164.70 crore for Q1FY27 as compared to Rs 1,717.22 crore for the corresponding quarter of the previous year.


Alembic Pharma Share Price

829.65 -4.95 (-0.59%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1949.00
Dr. Reddys Labs. 1172.00
Cipla 1472.00
Lupin 2360.00
Zydus Lifesciences 1115.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: